NCT07395687RecruitingPhase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 333 (estimated)
- First submitted
- 1 Feb 2026
- Start date
- 2 Feb 2026
- Primary completion date
- 14 Jan 2027
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07395687
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 333
- From 2 Feb 2026 to the primary completion date, 14 Jan 2027
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
Lab values
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
Who the study is looking for
- Male or female (sex at birth).
- For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
- For Japanese participants: both parents of Japanese descent.
- For Chinese participants: both parents of Chinese descent.
- For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
- Age at the time of signing the informed consent:
- For Part A: 18-55 years (both inclusive)
- For Part B: 18-65 years (both inclusive)
- For Part C: 18-55 years (both inclusive).
- BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):
- For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
- For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
- For Part C: 24-34.9 kg/m\^2 (both inclusive)
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Altasciences Clinical Company, Inc Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
| Altasciences Clinical LA, Inc. Coordinator of this site? Confirm its status | Cypress | United States | Recruiting |
| Altasciences Clinical Kansas, Inc. Coordinator of this site? Confirm its status | Overland Park | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.